Ona secured an $86.6 million venture round positioned among Spain’s largest biotech financings, according to Biocentury Finance reporting. The capital injection underscores continued appetite for new obesity and metabolic programs and supports expansion efforts as European biotech funds vie to convert early-stage assets into later clinical milestones.